Curevax
Brooklyn
About Curevax
CureVax is an emerging cancer treatment method in which a patient’s tumor cells are sampled, grown in the laboratory, and burst open in a very specific way in order to expose that specific cancer’s vulnerabilities. These processed shreds of the tumor cells are then injected back into the patient, stimulating his or her immune system to attack the cancer. A virus-lysed tumor cell vaccine is an active immunotherapeutic agent against tumors in patients. Tumor cells are removed from a patient, the cells are cultured in the laboratory and infected with live vaccinia virus’the active component of the vaccine that eradicated smallpox. During incubation, viral oncolysis occurs, in which the virus enters the tumor cells and breaks them open, spilling their contents, in a process known as lysis. The resulting viral oncolysate has lost the ability to grow as a tumor, but can be recognized by the patient’s immune system as the tumor. After extraction and processing, the viral oncolysate may be injected back into the patient to stimulate the immune response.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $9.9M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2016)
- Website: curevax.com
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/curevax-180693 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.